|Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008|
M Björkholm, L Ohm, S Eloranta, Å Derolf, M Hultcrantz, J Sjöberg, ...
Journal of Clinical Oncology 29 (18), 2514, 2011
|Duration of red blood cell storage and survival of transfused patients (CME)|
G Edgren, M Kamper‐Jørgensen, S Eloranta, K Rostgaard, B Custer, ...
Transfusion 50 (6), 1185-1195, 2010
|Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study|
A Leval, E Herweijer, A Ploner, S Eloranta, J Fridman Simard, J Dillner, ...
Journal of the National Cancer Institute 105 (7), 469-474, 2013
|Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study|
M Hultcrantz, SY Kristinsson, TML Andersson, O Landgren, S Eloranta, ...
Journal of Clinical Oncology 30 (24), 2995, 2012
|Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma|
E Herweijer, A Leval, A Ploner, S Eloranta, JF Simard, J Dillner, ...
Jama 311 (6), 597-603, 2014
|Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study|
SY Kristinsson, M Björkholm, TML Andersson, S Eloranta, PW Dickman, ...
haematologica 94 (12), 1714-1720, 2009
|Prospective study of human papillomavirus and risk of cervical adenocarcinoma|
LA Dahlström, N Ylitalo, K Sundström, J Palmgren, A Ploner, S Eloranta, ...
International journal of cancer 127 (8), 1923-1930, 2010
|Estimating and modelling cure in population-based cancer studies within the framework of flexible parametric survival models|
TML Andersson, PW Dickman, S Eloranta, PC Lambert
BMC medical research methodology 11 (1), 96, 2011
|15‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial (MCL 2): prolonged remissions without survival plateau|
CW Eskelund, A Kolstad, M Jerkeman, R Räty, A Laurell, S Eloranta, ...
British journal of haematology 175 (3), 410-418, 2016
|Prospective study of human papillomavirus (HPV) types, HPV persistence, and risk of squamous cell carcinoma of the cervix|
K Sundström, S Eloranta, P Sparén, LA Dahlström, A Gunnell, A Lindgren, ...
Cancer Epidemiology and Prevention Biomarkers 19 (10), 2469-2478, 2010
|Estimating the loss in expectation of life due to cancer using flexible parametric survival models|
TML Andersson, PW Dickman, S Eloranta, M Lambe, PC Lambert
Statistics in medicine 32 (30), 5286-5300, 2013
|Cancer incidence, survival and mortality: explaining the concepts|
L Ellis, LM Woods, J Estève, S Eloranta, MP Coleman, B Rachet
International journal of cancer 135 (8), 1774-1782, 2014
|Patterns of survival in lymphoplasmacytic lymphoma/waldenström macroglobulinemia: A population‐based study of 1,555 patients diagnosed in Sweden from 1980 to 2005|
SY Kristinsson, S Eloranta, PW Dickman, TML Andersson, I Turesson, ...
American journal of hematology 88 (1), 60-65, 2013
|Does socioeconomic status influence the prospect of cure from colon cancer–a population-based study in Sweden 1965–2000|
S Eloranta, PC Lambert, N Cavalli-Bjorkman, TML Andersson, B Glimelius, ...
European journal of cancer 46 (16), 2965-2972, 2010
|Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study|
M Hultcrantz, SR Wilkes, SY Kristinsson, TML Andersson, ÅR Derolf, ...
Journal of Clinical Oncology 33 (20), 2288-2295, 2015
|Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma|
P Fernberg, ET Chang, K Duvefelt, H Hjalgrim, S Eloranta, KM Sørensen, ...
Cancer causes & control 21 (5), 759-769, 2010
|How can we make cancer survival statistics more useful for patients and clinicians: an illustration using localized prostate cancer in Sweden|
S Eloranta, J Adolfsson, PC Lambert, P Stattin, O Akre, TML Andersson, ...
Cancer Causes & Control 24 (3), 505-515, 2013
|Reporting and incidence trends of hydatidiform mole in Sweden 1973–2004|
S Salehi, S Eloranta, ALV Johansson, M Bergström, M Lambe
Acta oncologica 50 (3), 367-372, 2011
|The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma–a Swedish population-based study|
M Mohammadi, Y Cao, I Glimelius, M Bottai, S Eloranta, KE Smedby
BMC cancer 15 (1), 850, 2015
|Pancreatic cancer; reporting and long-term survival in Sweden|
M Lambe, S Eloranta, A Wigertz, P Blomqvist
Acta Oncologica 50 (8), 1220-1227, 2011